Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades and downgrades, please see our analyst ratings page. Considering buying BSX stock? Here’s what analysts think: Read More: ...

Boston Scientific (BSX) closed the most recent trading day at $87, moving +0.27% from the previous trading session. The stock's performance was behind the S&P 500's daily gain of 0.47%. On the other hand, the Dow registered a gain of 0.79%, and the technology-centric Nasdaq increased by 0.28%.Heading into today, shares of the medical device manufacturer had gained 5.15% over the past month, outpacing the Medical sector's loss of 4.27% and the S&P 500's gain of 3.48% in that time.The investment community wil ...

The market expects Boston Scientific (BSX) to deliver a year-over-year increase in earnings on higher revenues when it reports results for the quarter ended September 2024. This widely-known consensus outlook is important in assessing the company's earnings picture, but a powerful factor that might influence its near-term stock price is how the actual results compare to these estimates.The stock might move higher if these key numbers top expectations in the upcoming earnings report, which is expected to be ...

Boston Scientific Corporation (BSX) is scheduled to report third-quarter 2024 results on Oct. 23, before the opening bell.In the last reported quarter, the company’s earnings per share of 62 cents exceeded the Zacks Consensus Estimate by 6.9%. BSX’s bottom line beat estimates in each of the trailing four quarters. The company delivered a trailing four-quarter earnings surprise of 7.18%, on average.Q3 EstimatesThe Zacks Consensus Estimate for third-quarter total revenues is pegged at $4.03 billion, suggestin ...

Have you been paying attention to shares of Boston Scientific (BSX) ? Shares have been on the move with the stock up 4.8% over the past month. The stock hit a new 52-week high of $87.79 in the previous session. Boston Scientific has gained 51.4% since the start of the year compared to the 8.6% move for the Zacks Medical sector and the 14.5% return for the Zacks Medical - Products industry.What's Driving the Outperformance?The stock has a great record of positive earnings surprises, as it hasn't missed our e ...

Boston Scientific (BSX) closed the most recent trading day at $86.20, moving -0.58% from the previous trading session. The stock fell short of the S&P 500, which registered a loss of 0.21% for the day. Elsewhere, the Dow lost 0.14%, while the tech-heavy Nasdaq lost 0.05%.Prior to today's trading, shares of the medical device manufacturer had gained 4.53% over the past month. This has outpaced the Medical sector's loss of 3.28% and lagged the S&P 500's gain of 5.94% in that time.Analysts and investors alike ...

After a commendable run in the first nine months of 2024, the S&P 500 is poised to gain in the year’s final three months. The S&P 500 has risen 20.8% in the first three quarters of the year, and historically whenever the broader index has gained over 20%, it has, on average, risen 2.1% in the fourth quarter, per Dow Jones Market Data.In the October-December quarter, the S&P 500’s median return was as high as 4.1%, and the index gained more than 77% of the time, added Dow Jones Market Data.The Federal Reserv ...

Boston Scientific (BSX) ended the recent trading session at $84.49, demonstrating a +0.42% swing from the preceding day's closing price. The stock outperformed the S&P 500, which registered a daily gain of 0.01%. Meanwhile, the Dow gained 0.09%, and the Nasdaq, a tech-heavy index, added 0.08%.The medical device manufacturer's shares have seen an increase of 3.7% over the last month, surpassing the Medical sector's loss of 3.6% and the S&P 500's gain of 1.21%.Investors will be eagerly watching for the perfor ...

Boston Scientific’s (BSX) growth is backed by its successful expansion of operations across different geographies outside the United States. Its recent acquisitions are expected to drive revenue growth in the long term. Consistent MedSurg market share gain is also highly encouraging. Meanwhile, headwinds such as currency movements raise concern for Boston Scientific.In the past year, this Zacks Rank #2 (Buy) company’s shares have rallied 63.3% compared with the industry’s 26.5% growth and the S&P 500 compos ...

-Company to also host virtual webcast with a cardiology business update-MARLBOROUGH, Mass., Oct. 2, 2024 /PRNewswire/ -- Boston Scientific Corporation (NYSE: BSX) will webcast its conference call discussing financial results and business highlights for the third quarter ended September 30, 2024, on Wednesday, October 23, 2024, at 8:00 a.m. ET. The call will be hosted by Mike Mahoney, chairman and chief executive officer, and Dan Brennan, executive vice president and chief financial officer. The company will ...